242 related articles for article (PubMed ID: 32550915)
21. Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer.
Sun XP; Dong X; Lin L; Jiang X; Wei Z; Zhai B; Sun B; Zhang Q; Wang X; Jiang H; Krissansen GW; Qiao H; Sun X
FEBS J; 2014 Jan; 281(1):115-28. PubMed ID: 24165223
[TBL] [Abstract][Full Text] [Related]
22. Emblica officinalis extract induces autophagy and inhibits human ovarian cancer cell proliferation, angiogenesis, growth of mouse xenograft tumors.
De A; De A; Papasian C; Hentges S; Banerjee S; Haque I; Banerjee SK
PLoS One; 2013; 8(8):e72748. PubMed ID: 24133573
[TBL] [Abstract][Full Text] [Related]
23. Hypoxia-induced increases in A549/CDDP cell drug resistance are reversed by RNA interference of HIF-1α expression.
Min L; Chen Q; He S; Liu S; Ma Y
Mol Med Rep; 2012 Jan; 5(1):228-32. PubMed ID: 21964646
[TBL] [Abstract][Full Text] [Related]
24. Hypoxia-inducible factor 1 alpha is required for the tumourigenic and aggressive phenotype associated with Rab25 expression in ovarian cancer.
Gomez-Roman N; Sahasrabudhe NM; McGregor F; Chalmers AJ; Cassidy J; Plumb J
Oncotarget; 2016 Apr; 7(16):22650-64. PubMed ID: 26967059
[TBL] [Abstract][Full Text] [Related]
25. Synergistic inhibition of GP130 and ERK signaling blocks chemoresistant bladder cancer cell growth.
Li X; He S; Tian Y; Weiss RM; Martin DT
Cell Signal; 2019 Nov; 63():109381. PubMed ID: 31374291
[TBL] [Abstract][Full Text] [Related]
26. HIF-1α-induced autophagy contributes to cisplatin resistance in ovarian cancer cells.
Long F; Liu W; Jia P; Wang H; Jiang G; Wang T
Pharmazie; 2018 Sep; 73(9):533-536. PubMed ID: 30223937
[TBL] [Abstract][Full Text] [Related]
27. A novel hypoxia-stimulated lncRNA HIF1A-AS3 binds with YBX1 to promote ovarian cancer tumorigenesis by suppressing p21 and AJAP1 transcription.
Xie W; Wang W; Meng S; Wu X; Liu X; Liu Y; Kang X; Su Y; Lv X; Guo L; Wang C
Mol Carcinog; 2023 Dec; 62(12):1860-1876. PubMed ID: 37589417
[TBL] [Abstract][Full Text] [Related]
28. NSC606985 induces apoptosis, exerts synergistic effects with cisplatin, and inhibits hypoxia-stabilized HIF-1alpha protein in human ovarian cancer cells.
Zhang N; Zhang H; Xia L; Zheng Y; Yu Y; Zhu Y; Chen G; Di W
Cancer Lett; 2009 Jun; 278(2):139-144. PubMed ID: 19339107
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of the Rho/ROCK pathway enhances the efficacy of cisplatin through the blockage of hypoxia-inducible factor-1α in human ovarian cancer cells.
Ohta T; Takahashi T; Shibuya T; Amita M; Henmi N; Takahashi K; Kurachi H
Cancer Biol Ther; 2012 Jan; 13(1):25-33. PubMed ID: 22336585
[TBL] [Abstract][Full Text] [Related]
30. The novel hypoxic cytotoxin, TX-2098 has antitumor effect in pancreatic cancer; possible mechanism through inhibiting VEGF and hypoxia inducible factor-1α targeted gene expression.
Miyake K; Nishioka M; Imura S; Batmunkh E; Uto Y; Nagasawa H; Hori H; Shimada M
Exp Cell Res; 2012 Aug; 318(13):1554-63. PubMed ID: 22472348
[TBL] [Abstract][Full Text] [Related]
31. HIF-1α-dependent miR-424 induction confers cisplatin resistance on bladder cancer cells through down-regulation of pro-apoptotic UNC5B and SIRT4.
Yu M; Ozaki T; Sun D; Xing H; Wei B; An J; Yang J; Gao Y; Liu S; Kong C; Zhu Y
J Exp Clin Cancer Res; 2020 Jun; 39(1):108. PubMed ID: 32522234
[TBL] [Abstract][Full Text] [Related]
32. Hypoxia-inducible factor 1 alpha promotes cancer stem cells-like properties in human ovarian cancer cells by upregulating SIRT1 expression.
Qin J; Liu Y; Lu Y; Liu M; Li M; Li J; Wu L
Sci Rep; 2017 Sep; 7(1):10592. PubMed ID: 28878214
[TBL] [Abstract][Full Text] [Related]
33. Hypoxia-inducible Factor-1α Suppression in Ovarian Clear-cell Carcinoma Cells by Silibinin Administration.
Miyazawa M; Yasuda M; Miyazawa M; Ogane N; Katoh T; Yano M; Hirasawa T; Mikami M; Ishimoto H
Anticancer Res; 2020 Dec; 40(12):6791-6798. PubMed ID: 33288572
[TBL] [Abstract][Full Text] [Related]
34. TCEB2 confers resistance to VEGF-targeted therapy in ovarian cancer.
Deng Z; Zhou J; Han X; Li X
Oncol Rep; 2016 Jan; 35(1):359-65. PubMed ID: 26531153
[TBL] [Abstract][Full Text] [Related]
35. Discovery of a novel quinoxalinhydrazide with a broad-spectrum anticancer activity.
Plasencia C; Grande F; Oshima T; Cao X; Yamada R; Sanchez T; Aiello F; Garofalo A; Neamati N
Cancer Biol Ther; 2009 Mar; 8(5):458-65. PubMed ID: 19221468
[TBL] [Abstract][Full Text] [Related]
36. The expression of platelet-activating factor receptor modulates the cisplatin sensitivity of ovarian cancer cells: a novel target for combination therapy.
Yu Y; Zhang X; Hong S; Zhang M; Cai Q; Zhang M; Jiang W; Xu C
Br J Cancer; 2014 Jul; 111(3):515-24. PubMed ID: 24921917
[TBL] [Abstract][Full Text] [Related]
37. Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma.
Liu F; Wang P; Jiang X; Tan G; Qiao H; Jiang H; Krissansen GW; Sun X
Cancer Sci; 2008 Oct; 99(10):2055-61. PubMed ID: 19016766
[TBL] [Abstract][Full Text] [Related]
38. Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy.
Yoon C; Chang KK; Lee JH; Tap WD; Hart CP; Simon MC; Yoon SS
Oncotarget; 2016 Jul; 7(28):42844-42858. PubMed ID: 27374091
[TBL] [Abstract][Full Text] [Related]
39. Hypoxia accelerates cancer invasion of hepatoma cells by upregulating MMP expression in an HIF-1alpha-independent manner.
Miyoshi A; Kitajima Y; Ide T; Ohtaka K; Nagasawa H; Uto Y; Hori H; Miyazaki K
Int J Oncol; 2006 Dec; 29(6):1533-9. PubMed ID: 17088993
[TBL] [Abstract][Full Text] [Related]
40. Oroxylin A reverses hypoxia-induced cisplatin resistance through inhibiting HIF-1α mediated XPC transcription.
Liu Y; Wang X; Li W; Xu Y; Zhuo Y; Li M; He Y; Wang X; Guo Q; Zhao L; Qiang L
Oncogene; 2020 Nov; 39(45):6893-6905. PubMed ID: 32978517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
